Avoro Capital Advisors Adds $27M in Revolution Medicines, Inc. ($RVMD)
Key Points
- Avoro Capital Advisors changed its Revolution Medicines, Inc. ($RVMD) stake by 8.0% last quarter, boosting to 2,344,444 shares worth $360.74 million.
- Wall Street's consensus rating on $RVMD is Strong Buy and an average price target of $187.29.
- $RVMD last traded around $153.87.
Avoro Capital Advisors increased its position in Revolution Medicines, Inc. ($RVMD) by 8.0% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,344,444 shares of Revolution Medicines, Inc. after buying 174,444 shares during the quarter. Avoro Capital Advisors's holdings in Revolution Medicines, Inc. were worth $360.74 million as of its most recent filing.
Revolution Medicines, Inc. ($RVMD) Stock
Revolution Medicines, Inc. Earnings
Analysts Set New Price Targets
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.